Core Insights - Connect Biopharma reported positive topline preliminary results for its Phase 1 clinical pharmacology study of intravenous (IV) rademikibart, indicating rapid improvement in lung function for asthma and COPD patients [1][2] Group 1: Clinical Study Results - Rademikibart administered as a single 300 mg 2-minute IV push produced rapid improvement in FEV1, with many patients experiencing improvements of ≥200 mL as early as 15 minutes post-dosing [1] - Mean FEV1 improvements of approximately 200 - 400 mL were maintained through Day 29 in asthma and COPD patients [1][4] - The study demonstrated that rademikibart has a unique beneficial effect on bronchodilation, independent of blocking IL-4Rα [2][5] Group 2: Study Design and Patient Demographics - The Phase 1 study was a single-dose, placebo-controlled trial evaluating IV rademikibart in healthy volunteers and patients with stable asthma and COPD [2] - In the patient cohort, the mean baseline FEV1 was 1.9 L for asthma patients and 1.55 L for COPD patients, with a majority being current smokers [2] Group 3: Future Developments - Recruitment is ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD, with topline data expected in mid-2026 [1][5] - The company plans to engage with the U.S. Food and Drug Administration (FDA) to align on a Phase 3 program following the Phase 2 studies [5] Group 4: Economic Impact and Treatment Paradigm - There is a significant health economic burden in the hospital setting for treating acute exacerbations in asthma and COPD, with current standard care relying on β-agonist bronchodilators and systemic steroids [3] - Rademikibart's rapid bronchodilation could provide a new treatment option that directly addresses underlying inflammatory drivers [3][5] Group 5: Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on transforming care for asthma and COPD, headquartered in San Diego, California [8] - The company is advancing rademikibart as a next-generation antibody targeting IL-4Rα, with significant unmet needs in the treatment of acute exacerbations [8]